Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.
Age Factors
Aged
Comorbidity
Disease Management
Disease Progression
Female
Forced Expiratory Volume
Germany
Health Care Costs
/ statistics & numerical data
Hospitalization
/ economics
Humans
Income
Male
Patient Acceptance of Health Care
Pulmonary Disease, Chronic Obstructive
/ complications
Retirement
/ economics
Sex Factors
Sick Leave
/ economics
Smoking
/ adverse effects
COPD
DMP
Direct costs
Healthcare utilization
Indirect costs
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
10 Oct 2019
10 Oct 2019
Historique:
received:
17
07
2019
accepted:
03
09
2019
entrez:
12
10
2019
pubmed:
12
10
2019
medline:
29
2
2020
Statut:
epublish
Résumé
Evidence on the economic impact of chronic obstructive pulmonary disease (COPD) for third-party payers and society based on large real world datasets are still scarce. Therefore, the aim of this study was to estimate the economic impact of COPD severity and its comorbidities, stratified by GOLD grade, on direct and indirect costs for an unselected population enrolled in the structured German Disease Management Program (DMP) for COPD. All individuals enrolled in the DMP COPD were included in the analysis. Patients were only excluded if they were not insured or not enrolled in the DMP COPD the complete year before the last DMP documentation (at physician visit), had a missing forced expiratory volume in 1 s (FEV More severe COPD was significantly associated with higher healthcare utilization, work absence, and premature retirement. Adjusted annual costs for GOLD grade 1 to 4 amounted to €3809 [€3691-€3935], €4284 [€4176-€4394], €5548 [€5328-€5774], and €8309 [€7583-9065] for direct costs, and €11,784 [€11,257-€12,318], €12,985 [€12,531-13,443], €15,805 [€15,034-€16,584], and €19,402 [€17,853-€21,017] for indirect costs. Comorbidities had significant additional effects on direct and indirect costs with factors ranging from 1.19 (arthritis) to 1.51 (myocardial infarction) in direct and from 1.16 (myocardial infarction) to 1.27 (cancer) in indirect costs. The findings indicate that more severe GOLD grades in an unselected COPD population enrolled in a structured DMP are associated with tremendous additional direct and indirect costs, with comorbidities significantly increase costs. In direct cost category hospitalization and in indirect cost category premature retirement were the main cost driver. From a societal perspective prevention and interventions focusing on disease control, and slowing down disease progression and strengthening the ability to work would be beneficial in order to realize cost savings in COPD.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence on the economic impact of chronic obstructive pulmonary disease (COPD) for third-party payers and society based on large real world datasets are still scarce. Therefore, the aim of this study was to estimate the economic impact of COPD severity and its comorbidities, stratified by GOLD grade, on direct and indirect costs for an unselected population enrolled in the structured German Disease Management Program (DMP) for COPD.
METHODS
METHODS
All individuals enrolled in the DMP COPD were included in the analysis. Patients were only excluded if they were not insured or not enrolled in the DMP COPD the complete year before the last DMP documentation (at physician visit), had a missing forced expiratory volume in 1 s (FEV
RESULTS
RESULTS
More severe COPD was significantly associated with higher healthcare utilization, work absence, and premature retirement. Adjusted annual costs for GOLD grade 1 to 4 amounted to €3809 [€3691-€3935], €4284 [€4176-€4394], €5548 [€5328-€5774], and €8309 [€7583-9065] for direct costs, and €11,784 [€11,257-€12,318], €12,985 [€12,531-13,443], €15,805 [€15,034-€16,584], and €19,402 [€17,853-€21,017] for indirect costs. Comorbidities had significant additional effects on direct and indirect costs with factors ranging from 1.19 (arthritis) to 1.51 (myocardial infarction) in direct and from 1.16 (myocardial infarction) to 1.27 (cancer) in indirect costs.
CONCLUSION
CONCLUSIONS
The findings indicate that more severe GOLD grades in an unselected COPD population enrolled in a structured DMP are associated with tremendous additional direct and indirect costs, with comorbidities significantly increase costs. In direct cost category hospitalization and in indirect cost category premature retirement were the main cost driver. From a societal perspective prevention and interventions focusing on disease control, and slowing down disease progression and strengthening the ability to work would be beneficial in order to realize cost savings in COPD.
Identifiants
pubmed: 31601216
doi: 10.1186/s12931-019-1179-7
pii: 10.1186/s12931-019-1179-7
pmc: PMC6785905
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
215Subventions
Organisme : Gemeinsamer Bundesausschuss (GB-A) (DE)
ID : 01VSF16025
Références
Circulation. 2014 Apr 8;129(14):1493-501
pubmed: 24573351
Cost Eff Resour Alloc. 2006 Oct 16;4:17
pubmed: 17042950
Pneumologie. 2004 Dec;58(12):837-44
pubmed: 15597250
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751416
Gesundheitswesen. 2013 Jul;75(7):413-23
pubmed: 23553190
Pneumologie. 1999 Apr;53(4):199-206
pubmed: 10409862
BMC Health Serv Res. 2012 Oct 31;12:379
pubmed: 23113880
Annu Rev Public Health. 2007;28:95-111
pubmed: 17112339
Dtsch Med Wochenschr. 2001 Mar 30;126(13):353-9
pubmed: 11332229
Health Qual Life Outcomes. 2010 Apr 15;8:39
pubmed: 20398326
Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:871-88
pubmed: 25210449
PLoS One. 2015 Jul 13;10(7):e0132670
pubmed: 26168154
J Med Econ. 2012;15(6):1176-82
pubmed: 22812689
Respir Med. 2011 Oct;105(10):1516-22
pubmed: 21684731
J Health Econ. 1997 Apr;16(2):249-55; discussion 257-9
pubmed: 10173080
Chest. 2012 Oct;142(4):973-981
pubmed: 22406959
Respir Med. 2016 Feb;111:39-46
pubmed: 26725462
Respir Med. 2013 Dec;107(12):1931-8
pubmed: 23910072
Sleep Breath. 2009 Nov;13(4):317-23
pubmed: 19484281
Dtsch Med Wochenschr. 2001 Jul 13;126(28-29):803-8
pubmed: 11499261
Int J Chron Obstruct Pulmon Dis. 2017 Dec 04;12:3437-3448
pubmed: 29270005
Value Health. 2008 Jul-Aug;11(4):539-44
pubmed: 18194408
Pharmacoeconomics. 2005;23(2):105-11
pubmed: 15748085
Int J Chron Obstruct Pulmon Dis. 2017 Sep 28;12:2787-2793
pubmed: 29026296
COPD. 2006 Dec;3(4):203-9
pubmed: 17361501
Eur J Heart Fail. 2005 Jun;7(4):677-83
pubmed: 15921811
Chest. 2015 Jul;148(1):138-150
pubmed: 25675282
PLoS One. 2015 Apr 13;10(4):e0123292
pubmed: 25875204
BMC Public Health. 2011 Aug 01;11:612
pubmed: 21806798
Pharmacoeconomics. 1992 Jul;2(1):1-4
pubmed: 10146974
Int J Tuberc Lung Dis. 2014 Jun;18(6):737-43
pubmed: 24903947
J Health Econ. 2005 May;24(3):465-88
pubmed: 15811539
Gesundheitswesen. 2015 Jan;77(1):53-61
pubmed: 25025287
BMC Cardiovasc Disord. 2010 Feb 18;10:8
pubmed: 20167091
Int J Chron Obstruct Pulmon Dis. 2011;6:533-42
pubmed: 22069365
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
COPD. 2013 Dec;10(6):629-39
pubmed: 23845002
Health Policy. 2007 Jan;80(1):86-96
pubmed: 16600418
J Health Econ. 1995 Jun;14(2):171-89
pubmed: 10154656
Pneumologie. 2011 Jun;65(6):379-87
pubmed: 21370222
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Pharmacoeconomics. 1998 Jan;13(1 Pt 1):1-7
pubmed: 10175982
J Health Econ. 2004 May;23(3):525-42
pubmed: 15120469
Respir Med. 2010 May;104(5):697-704
pubmed: 19954941
Healthcare (Basel). 2019 Mar 01;7(1):null
pubmed: 30832210
Int J Chron Obstruct Pulmon Dis. 2017 Sep 11;12:2711-2721
pubmed: 28979113
Int J Chron Obstruct Pulmon Dis. 2019 Jul 05;14:1423-1439
pubmed: 31308648
Clinicoecon Outcomes Res. 2014 Jul 16;6:349-56
pubmed: 25075195